Exenatide and pramlintide: New glucose-lowering agents for treating diabetes mellitus
Byron J. Hoogwerf, MD
Department of Endocrinology, Diabetes, and Metabolism, Cleveland Clinic
Address: Byron J. Hoogwerf, MD, Department of Endocrinology, Diabetes, and Metabolism, A53, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail firstname.lastname@example.org
The author has indicated that he serves on an advisory committee to develop educational materials for the Amylin/Lilly Synergy partnership.
ABSTRACTInsulin is not the only hormone that regulates plasma glucose levels. Glucagon-like peptide 1 (GLP-1), produced in the small intestine, and amylin, produced by beta cells in the pancreas, also have glucose-lowering effects. Synthetic analogues of these hormones are now available for clinical use.